Back to matchesWe found a matchYour institution may have rights to this item. Sign in to continue.TitleSAFETY AND EARLY DATA FROM A PHASE II TRIAL OF PEMBROLIZUMAB (PEM) AND ENTINOSTAT (ENT) IN RELAPSED AND REFRACTORY (R/R) HODGKIN LYMPHOMA (HL) AND FOLLICULAR LYMPHOMA (FL).AuthorsSermer, D.; Vardhana, S.; Batlevi, C.; Hamilton, A.; Moskowitz, A.; Caron, P.; Moskowitz, C.; Matasar, M.; Biggar, E.; Leung, E.; Yahalom, J.; Rademaker, J.; Dogan, A.; Seshan, V.; Younes, A.SubjectsHODGKIN'S disease; LYMPHOMASPublicationHematological Oncology, 2019, Vol 37, p331ISSN0278-0232Publication typeArticleDOI10.1002/hon.143_2630